Accelerated at-home tDCS for depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, three-arm study will enroll 30 adults with major depressive disorder who have not used antidepressants. Participants will receive either active at-home transcranial direct current stimulation, sham stimulation, or a waitlist control for three weeks, with the control groups crossing over to active treatment after the initial phase. Feasibility outcomes will include device usability and patient adherence, while effectiveness will be assessed through clinical ratings and tolerability. The investigation builds on prior work (GSUND DAHOAM) to explore rapid, home-based intervention options for depression. The study is conducted at the University of Regensburg in Germany and is led by the psychiatry and neuromodulation centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sex: female, male, non-binary
* Age: 18-70 years
* Diagnosis of depression: no current or past psychiatric medication (current episode and history)
* Provision of informed consent to participate
* Sufficient proficiency in the German language

Exclusion Criteria:

* Presence of contraindications for tDCS (e.g., electrical implants or metallic objects in the body such as a cardiac pacemaker or insulin pump, dermatological conditions affecting the scalp)
* Neurological disorders (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformations, or a history of severe head injury)
* Participation in another clinical trial on depression within the 3 months prior to treatment initiation
* Pregnancy or breastfeeding

Where it's running

• Psychiatry and Psychotherapy, Center of Neuromodulation / TMS, University Regensburg
  Regensburg, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Berthold Langguth, Prof, PhD — University of Regensburg
• Study coordinator: Stefan Schoisswohl, PD, PhD
• Email: stefan.schoisswohl@ukr.de
• Phone: +499419411284

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

• A Phase 3 test of DT120 for major depressive disorder

  DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.

  Recruiting at 23 sites Phase 3 Definium Therapeutics US, Inc. · Little Rock, Arkansas and 25 other locations · NCT07592689

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.